

# Oncology Biomarkers: Global Markets

<https://marketpublishers.com/r/O3925AAD1DAAEN.html>

Date: June 2023

Pages: 186

Price: US\$ 5,500.00 (Single User License)

ID: O3925AAD1DAAEN

## Abstracts

### Report Scope:

This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.

This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.

### Report Includes:

21 data tables and 60 additional tables

An in-depth analysis of the global oncology biomarkers market

Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028

Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region

Discussion on market drivers, challenges and key market strategies and trends

Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development

Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities

Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche Ltd., Merck KGaA, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Methodology and Information Sources  
Geographic Breakdown  
Analyst's Credentials  
BCC Custom Research  
Related BCC Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 MARKET OUTLOOK**

### **CHAPTER 4 MARKET AND TECHNOLOGY BACKGROUND**

Overview of Biomarkers  
Classification of Biomarkers  
Types of Biomarkers  
Biomarker Discovery, Verification and Validation  
Overview of Cancer  
Cancer/Oncology Biomarkers  
Oncology Biomarkers Testing Methods  
Oncology Biomarkers Testing Types  
Biomarker Test Development and Marketing

### **CHAPTER 5 MARKET DYNAMICS**

Drivers  
Rising Incidence of Cancer  
Increasing Use of Biomarkers in Drug Discovery and Development  
Developments in Analytical Technologies and Assay Methods  
Increased Availability and Ease of Biomarker Testing  
Support from Regulatory Agencies  
Barriers  
Inadequate Patient Access to and Insurance Coverage of Biomarker Testing

Technical Errors and Delayed Test Results  
Low Provider and Patient Awareness  
Suboptimal Tissue Procurement and Triaging  
Shortages of Laboratories and Personnel

## **CHAPTER 6 MARKET BREAKDOWN BY BIOMARKER TYPE**

Protein Biomarkers  
Protein Biomarkers Profiling Technologies  
Genomic Biomarker  
Genomic Biomarkers Profiling Technologies  
Other Biomarkers  
Metabolomic Biomarkers  
Cellular Biomarkers  
Global Market for Oncology Biomarkers, by Biomarker Type  
Protein Biomarkers  
Genomic Biomarkers  
Other Biomarkers

## **CHAPTER 7 MARKET BREAKDOWN BY APPLICATION**

Life Science Research  
Risk Assessment and Screening  
Diagnostics  
Prognostics  
Therapeutic Selection and Clinical Trials  
Monitoring  
Response Monitoring  
Recurrence/Minimal Residual Disease (MRD) Monitoring  
Global Market for Oncology Biomarkers by Application  
Life Science Research  
Risk Assessment and Screening  
Diagnostics  
Prognostics  
Therapeutic Selection and Clinical Trials  
Monitoring

## **CHAPTER 8 MARKET BREAKDOWN BY CANCER TYPE**

Market Overview

Breast Cancer

Lung Cancer

Colorectal Cancer (CRC)

Prostate Cancer

Bladder Cancer

Melanoma

Leukemia

Others

Ovarian Cancer

Liver Cancer

Thyroid Cancer

Cervical Cancer

Kidney Cancer

Endometrial Cancer

Global Market for Oncology Biomarkers by Cancer Type

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Bladder Cancer

Melanoma

Leukemia

Other Cancers

## **CHAPTER 9 MARKET BREAKDOWN BY REGION**

Global Market for Oncology Biomarkers by Region

North America

Market Revenue by Application

Market Revenue by Country

Europe

Market Revenue by Application

Market Revenue by Country

Asia-Pacific

Market Revenue by Application

Market Revenue by Country

Rest of World

Market Revenue by Application

## **CHAPTER 10 IMPACT OF COVID-19**

### Overview

Implications on Cancer Diagnosis

Implications on Cancer Treatment

Impact on Oncology Biomarkers Market

## **CHAPTER 11 EMERGING TRENDS AND TECHNOLOGIES IN THE MARKET**

Emerging Technologies and Trends in the Market

Liquid Biopsy

Circulating Free Nucleic Acids

Circulating Cell-Free DNA (CfDNA)

“Organ Agnostic” Biomarker Testing

PD-L1

Homologous Recombination Deficiency (HRD)

Blood Test for Early-Stage Cancer Detection

## **CHAPTER 12 COMPETITIVE LANDSCAPE**

### Overview

Mergers and Acquisitions

SWOT Analysis for Global Oncology Biomarker Market

Porter’s Five Forces Analysis of Global Oncology Biomarker Market

## **CHAPTER 13 COMPANY PROFILES**

AGENDIA INC.

ABBOTT

AGILENT TECHNOLOGIES INC.

BIOCARTIS NV

BIOMERIEUX S.A.

BIO-RAD LABORATORIES INC.

BECTON, DICKINSON & CO.

EXACT SCIENCES CORP.

F. HOFFMANN-LA ROCHE AG

GUARDANT HEALTH INC.

HOLOGIC INC.

ILLUMINA INC.  
LEICA BIOSYSTEMS  
MERCK KGAA  
MYRIAD GENETICS INC.  
QIAGEN N.V.  
SIEMENS HEALTHINEERS AG  
THERMO FISHER SCIENTIFIC INC.  
VERACYTE INC.

## **CHAPTER 14 APPENDIX: ACRONYMS**

## List Of Tables

### LIST OF TABLES

Summary Table: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028

Table 1: Different Categories of Biomarkers

Table 2: Multiple Paths to Market for Biomarker Test

Table 3: Biomarkers: Drug Development

Table 4: FDA Issued Letters of Support to Cancer Biomarkers

Table 5: Three Biggest Barriers to Biomarker Testing

Table 6: Selected Protein Biomarkers Used in Oncology

Table 7: Examples of Genomic Biomarkers

Table 8: NGS Methods Used in Oncology

Table 9: PMA Approved NGS Oncology Panel, Somatic or Germline Variant Detection System

Table 10: Selected Genomic Biomarkers Used in Oncology

Table 11: Potential Applications of CTC-Based Diagnostics

Table 12: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028

Table 13: FDA Novel Drug Approvals with Predictive Biomarkers, Jan. 2021–Jan. 2023

Table 14: Total Number of Biomarkers Used in FDA Approved Therapeutic Selection Tests or CDx, by Cancer Type, 2022

Table 15: Global Market for Oncology Biomarkers, by Application, Through 2028

Table 16: NIH Funding for Cancer Research, by Cancer Type, Through 2024

Table 17: Total Number of Drugs with Approved CDx, by Cancer Type, 2021

Table 18: Estimated Numbers for All Cancers Excl. Non-Melanoma Skin Cancer in 2020

Table 19: Selected Key Biomarkers for Breast Cancer

Table 20: Biomarkers Used in Breast Cancer Therapy Selection

Table 21: Selected Key Biomarkers for Lung Cancer

Table 22: Biomarkers Used in Lung Cancer Therapy Selection

Table 23: Selected CRC Screening Products/Tests

Table 24: Selected Key Biomarkers for CRC

Table 25: Biomarkers Used in CRC Therapy Selection

Table 26: Selected Prostate Cancer Screening Tests

Table 27: Biomarkers Used in Prostrate Cancer Therapy Selection

Table 28: Selected Key Biomarkers for Prostate Cancer

Table 29: Selected Key Biomarkers for Bladder Cancer

Table 30: Biomarkers Used in Bladder Cancer Therapy Selection

Table 31: Selected Key Biomarkers for Melanoma



Table 32: Biomarkers Used in Melanoma Therapy Selection

Table 33: Selected Key Biomarkers for Leukemia

Table 34: Biomarkers Used in Leukemia Therapy Selection

Table 35: Selected Key Biomarkers for Ovarian Cancer

Table 36: Biomarkers Used in Ovarian Cancer Therapy Selection

Table 37: Global Market for Oncology Biomarkers, by Cancer Type, Through 2028

Table 38: Global Market for Breast Cancer Biomarkers, by Biomarker Type, Through 2028

Table 39: Global Market for Lung Biomarkers, by Biomarker Type, Through 2028

Table 40: Global Market for Colorectal Cancer Biomarkers, by Biomarker Type, Through 2028

Table 41: Global Market for Prostate Cancer Biomarkers, by Biomarker Type, Through 2028

Table 42: Global Market for Bladder Cancer Biomarkers, by Biomarker Type, Through 2028

Table 43: Global Market for Melanoma Biomarkers, by Biomarker Type, Through 2028

Table 44: Global Market for Leukemia Biomarkers, by Biomarker Type, Through 2028

Table 45: Global Market for Other Cancers Biomarkers, by Biomarker Type, Through 2028

Table 46: Global Market for Oncology Biomarkers, by Region, Through 2028

Table 47: Estimated Numbers of New Cases and Deaths for Common Cancer Type in the U.S. in 2023

Table 48: North American Market for Oncology Biomarkers, by Application, Through 2028

Table 49: North American Market for Oncology Biomarkers, by Country, Through 2028

Table 50: Challenges to Biomarker Testing in Europe

Table 51: Demographic, Cancer and Healthcare Statistics for Selected European Countries

Table 52: Estimated Cancer Incidence and Mortality, Age Standardized Rate in the EU Countries, by Cancer Type, 2020

Table 53: European Market for Oncology Biomarkers, by Application, Through 2028

Table 54: European Market for Oncology Biomarkers, by Country, Through 2028

Table 55: Oncology Statistics in Select Asia-Pacific Countries, 2020

Table 56: Estimated Cancer Cases in Asia-Pacific Countries, by Notable Cancer Types, 2020

Table 57: Asia-Pacific Market for Oncology Biomarkers, by Application, Through 2028

Table 58: Asia-Pacific Market for Oncology Biomarkers, by Country, Through 2028

Table 59: Cancer Statistics, South America and Africa, 2020

Table 60: RoW Market for Oncology Biomarkers, by Application, Through 2028

Table 61: Selected CfDNA-Based Cancer Tests

Table 62: Leading Market Players in Oncology Biomarkers Market, 2022

Table 63: Recent Mergers and Acquisitions in Oncology Biomarkers Market, 2020-2022

Table 64: Porter's Five Forces Analysis: Global Oncology Biomarkers Market

Table 65: Agilent Technologies Inc.: Selected Key Developments, January 2021-March 2023

Table 66: Biocartis: Selected Key Developments, January 2020-March 2023

Table 67: Bio-Rad Laboratories: Selected Key Developments, January 2020-March 2023

Table 68: BD: Business Segments

Table 69: BD: Selected Key Developments, January 2020-March 2023

Table 70: Exact Sciences Corp.: Key Developments, January 2021 to December 2022

Table 71: Roche: Selected Recent Developments, January 2021 to March 2023

Table 72: Guardant Health: Key Developments, 2021-2022

Table 73: Hologic Inc.: Key Developments, January 2021 to December 2022

Table 74: Illumina Inc: Key Developments, 2021 and 2022

Table 75: Leica Biosystems: Key Developments, January 2021 to December 2022

Table 76: Myriad Genetics: Key Developments, January 2021 to December 2022

Table 77: Qiagen: Key Recent Developments, 2021-April 2023

Table 78: Thermo Fisher Scientific Inc.: Key Developments, January 2021 to January 2023

Table 79: Veracyte: Key Recent Developments, Jan 2021-Jan 2023

Table 80: Abbreviations Used in This Report

## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028

Figure 1: Biomarker Types Categorized by Application and Use in Drug Development and Disease Management

Figure 2: Molecular and Imaging Biomarkers

Figure 3: Biomarker Discovery, Verification and Validation

Figure 4: Cancer Care Spectrum

Figure 5: Types of Biomarker Testing and Their Definitions

Figure 6: Biomarkers in Personalized Treatment

Figure 7: Global Cancer Incidence, by Region, 2020

Figure 8: Global Cancer Incidence, by Region, 2020 vs. 2040

Figure 9: Distribution Shares of R&D Investment in Drug Development, by Function, 2020

Figure 10: Overview of Biomarker Test Benefits for Each Stakeholder

Figure 11: Barriers to the Use of Biomarker Tests Throughout the Patient Journey

Figure 12: Top Barriers to Biomarker Testing in the U.S., 2021

Figure 13: Common Biomarker Testing Methodologies

Figure 14: Four Main Classes of Genomic Alterations

Figure 15: Types of Genomic Biomarkers

Figure 16: Genomic Biomarker Testing Methods

Figure 17: Key Advantages of NGS for Precision Oncology Applications

Figure 18: Evolution of Biomarkers in Clinical Practice

Figure 19: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028

Figure 20: Global Market Shares of Oncology Biomarkers, by Biomarker Type, 2022

Figure 21: Hallmark of Cancer

Figure 22: Stages of Cancer

Figure 23: Companion Diagnostics Co-Development Process from Biomarker Discovery to Regulatory Approval

Figure 24: Clinical Applications of Biomarkers in Oncology

Figure 25: Global Market for Oncology Biomarkers, by Application, 2020-2028

Figure 26: Global Market Shares of Oncology Biomarkers, by Application, 2022

Figure 27: Five-Year Overall Survival Rates in the U.S., by Cancer Type

Figure 28: Global Market for Oncology Biomarkers, by Cancer Type, 2020-2028

Figure 29: Global Market Shares of Oncology Biomarkers, by Cancer Type, 2022

Figure 30: Global Market Shares of Breast Cancer Biomarkers, by Biomarker Type,

2022

Figure 31: Global Market Shares of Lung Biomarkers, by Biomarker Type, 2022

Figure 32: Global Market Shares of Colorectal Cancer Biomarkers, by Biomarker Type, 2022

Figure 33: Global Market Shares of Prostate Cancer Biomarkers, by Biomarker Type, 2022

Figure 34: Global Market Shares of Bladder Cancer Biomarkers, by Biomarker Type, 2022

Figure 35: Global Market Shares of Melanoma Biomarkers, by Biomarker Type, 2022

Figure 36: Global Market Shares of Leukemia Biomarkers, by Biomarker Type, 2022

Figure 37: Global Market Shares of Other Cancers Biomarkers, by Biomarker Type, 2022

Figure 38: Global Market for Oncology Biomarkers, by Region, 2020-2028

Figure 39: Global Market Shares of Oncology Biomarkers, by Region, 2022

Figure 40: NIH's Cancer and Cancer Genomics Research Funding, by Year, 2018-2024

Figure 41: North American Market Shares of Oncology Biomarkers, by Application, 2022

Figure 42: European Market Shares of Oncology Biomarkers, by Application, 2022

Figure 43: Asia-Pacific Market Shares of Oncology Biomarkers, by Application, 2022

Figure 44: RoW Market Shares of Oncology Biomarkers, by Application, 2022

Figure 45: Emerging Trends/Technologies in the Oncology Biomarkers Market

Figure 46: Advantages of Liquid Biopsy

Figure 47: PubMed Article Count: "Liquid Biopsy", 2014-2022

Figure 48: Pan-Cancer Genomic Biomarkers

Figure 49: SWOT Analysis of the Global Oncology Biomarkers Market

Figure 50: Abbott: Diagnostics Revenue, 2020-2022

Figure 51: Abbott: Diagnostics Market Share, by Business Segment, 2022

Figure 52: Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2020-2022

Figure 53: Biocartis: Annual Net Revenue, 2020-2022

Figure 54: Biocartis: Market Share, by Business Segment, 2022

Figure 55: BioMérieux SA: Annual Net Revenue, 2020-2022

Figure 56: BioMérieux SA: Market Share, by Application, 2022

Figure 57: Bio-Rad Laboratories: Annual Net Revenue, 2020-2022

Figure 58: Bio-Rad Laboratories: Market Share, by Business Segment, 2022

Figure 59: BD's Biosciences Segment: Annual Revenue, 2020-2022

Figure 60: Exact Sciences Corp.: Annual Net Revenue, 2020-2022

Figure 61: Exact Sciences Corp.: Market Share, by Business Segment, 2022

Figure 62: F. Hoffmann-La Roche Ltd.'s Diagnostics Division: Annual Revenue, 2020-2022

Figure 63: F. Hoffmann-La Roche Ltd.'s Diagnostics Division: Market Share, by Customer Area, 2022

Figure 64: Guardant Health: Annual Net Revenue, 2020-2022

Figure 65: Guardant Health: Market Share, by Segment, 2022

Figure 66: Hologic Inc.: Annual Net Revenue, 2020-2022

Figure 67: Hologic Inc.: Market Share, by Business Segment, 2022

Figure 68: Illumina Inc.: Annual Net Revenue, 2020-2022

Figure 69: Illumina Inc.: Market Share, by Business Segment, 2022

Figure 70: Merck KGaA: Annual Revenue, 2020-2022

Figure 71: Merck KGaA: Market Share, by Business Segment, 2022

Figure 72: Myriad Genetics: Annual Net Revenue, 2021 and 2022

Figure 73: Myriad Genetics: Market Share, by Business Segment, 2022

Figure 74: Qiagen: Annual Net Revenue, 2020-2022

Figure 75: Qiagen: Market Share, by Product Type, 2022

Figure 76: Siemens Healthineers AG: Annual Net Revenue, 2020-2022

Figure 77: Siemens Healthineers AG: Market Share, by Business Segment, 2022

Figure 78: Thermo Fisher Scientific Inc.: Annual Revenue, 2020-2022

Figure 79: Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2022

Figure 80: Veracyte: Annual Revenue, 2020-2022

Figure 81: Veracyte: Market Share, by Business Segment, 2022

## I would like to order

Product name: Oncology Biomarkers: Global Markets

Product link: <https://marketpublishers.com/r/O3925AAD1DAAEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3925AAD1DAAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970